Q-omics provides the consensus-scored PIK3CD profile across patient tissues and cancer cell-line models. PIK3CD expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, PIK3CD is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, PIK3CD protein abundance shows 23,576 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUAD, HNSC, and LSCC as cancer lineages where PIK3CD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PIK3CD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PIK3CD survival associations across molecular data types. PIK3CD RNA expression shows survival associations in the most cancer types (23), followed by mutation status (9) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PIK3CD RNA expression–survival associations across cancer types. High PIK3CD expression shows unfavorable associations in LGG and KIRC, but favorable associations in LUAD, CESC, BRCA and ESCA. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for PIK3CD RNA expression.
This table summarizes PIK3CD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PIK3CD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PIK3CD shows lower tumor expression in COAD, UCEC, BRCA and KICH and higher tumor expression in HNSC and KIRC. The HNSC box plot shows higher PIK3CD RNA expression in tumor versus normal tissue (log2 FC = +1.487, t-test p < 0.001).
This table shows molecular features associated with PIK3CD in patient tissues and cancer cell lines. In patient samples, PIK3CD shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PIK3CD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BREAST.
